NCT05357573View on ClinicalTrials.gov

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

November 22, 2023

Study Completion Date

December 22, 2023

Conditions
Tumor-Induced Osteomalacia (TIO)
Interventions
DRUG

KRN23

KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL

Trial Locations (3)

Unknown

Peking Union Medical College Hospital, Beijing

West China Hospital, Sichuan University, Chengdu

Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY